Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Ovid Therapeutics Inc. (OVID)

1.79   -0.06 (-3.24%) 12-05 16:00
Open: 1.82 Pre. Close: 1.85
High: 1.82 Low: 1.78
Volume: 108,741 Market Cap: 126(M)

Technical analysis

as of: 2022-12-06 8:20:24 AM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 2.16     One year: 2.52
Support: Support1: 1.57    Support2: 1.4
Resistance: Resistance1: 1.85    Resistance2: 2.16
Pivot: 1.74
Moving Average: MA(5): 1.8     MA(20): 1.69
MA(100): 1.9     MA(250): 2.42
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 90.4     %D(3): 91
RSI: RSI(14): 55.9
52-week: High: 3.54  Low: 1.4
Average Vol(K): 3-Month: 98 (K)  10-Days: 50 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ OVID ] has closed below upper band by 36.4%. Bollinger Bands are 0.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.82 - 1.83 1.83 - 1.84
Low: 1.76 - 1.77 1.77 - 1.78
Close: 1.77 - 1.79 1.79 - 1.81

Company Description

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Headline News

Mon, 05 Dec 2022
Basketball roundup: Ellie Baynes' triple-double leads Laingsburg - Lansing State Journal

Mon, 05 Dec 2022
Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting -

Mon, 05 Dec 2022
The Mail - The New Yorker

Tue, 29 Nov 2022
New Statesman Positive Impact Awards recognise eye health partnership - Association of Optometrists

Mon, 28 Nov 2022
Like fragile ice, anger passes away in time. — Ovid - The Tribune India

Tue, 15 Nov 2022
Ovid City Council grapples with budget in Monday meeting - Argus Press

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 70 (M)
% Held by Insiders 3.755e+007 (%)
% Held by Institutions 19.1 (%)
Shares Short 283 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -6.934e+007
EPS Est Next Qtl -0.63
EPS Est This Year -3.89
EPS Est Next Year -2.75
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -4
Return on Assets (ttm) 787.5
Return on Equity (ttm) -23.5
Qtrly Rev. Growth 1.46e+006
Gross Profit (p.s.) 0
Sales Per Share -35.22
EBITDA (p.s.) 1.812e+008
Qtrly Earnings Growth -1
Operating Cash Flow 0 (M)
Levered Free Cash Flow -58 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.06
Price to Cash Flow 1.01

Stock Dividends

Dividend 0
Forward Dividend 277660
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.